These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 19256181)

  • 1. Epidemiology of respiratory syncytial virus in various regions within North Carolina during multiple seasons.
    Wilfret DA; Baker BT; Palavecino E; Moran C; Benjamin DK
    N C Med J; 2008; 69(6):447-52. PubMed ID: 19256181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Respiratory syncytial virus: seasonal data for regions of Florida and implications for palivizumab.
    Bauman J; Eggleston M; Oquist N; Malinoski F
    South Med J; 2007 Jul; 100(7):669-76. PubMed ID: 17639745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
    Romero JR
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of a novel web-based prior approval application for palivizumab prophylaxis of respiratory syncytial virus in a state Medicaid program.
    Lundeen K; Pfeiffenberger T; Jacobson Vann J; O'Brien T; Sampson C; Wegner S
    J Manag Care Pharm; 2013 Mar; 19(2):115-24. PubMed ID: 23461427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of respiratory syncytial virus surveillance data to optimize the timing of immunoprophylaxis.
    Panozzo CA; Stockman LJ; Curns AT; Anderson LJ
    Pediatrics; 2010 Jul; 126(1):e116-23. PubMed ID: 20547651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Timing of monoclonal antibody for seasonal RSV prophylaxis in the United Kingdom.
    Goddard NL; Cooke MC; Gupta RK; Nguyen-Van-Tam JS
    Epidemiol Infect; 2007 Jan; 135(1):159-62. PubMed ID: 16753078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses.
    Wang D; Bayliss S; Meads C
    Health Technol Assess; 2011 Jan; 15(5):iii-iv, 1-124. PubMed ID: 21281564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Description of the outcomes of prior authorization of palivizumab for prevention of respiratory syncytial virus infection in a managed care organization.
    Buckley BC; Roylance D; Mitchell MP; Patel SM; Cannon HE; Dunn JD
    J Manag Care Pharm; 2010; 16(1):15-22. PubMed ID: 20044843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program.
    Wegner S; Vann JJ; Liu G; Byrns P; Cypra C; Campbell W; Stiles A
    Pediatrics; 2004 Dec; 114(6):1612-9. PubMed ID: 15574623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Palivizumab prophylaxis against respiratory syncytial virus infection in patients younger than 2 years of age with congenital heart disease.
    Mohammed MHA; Agouba R; Obaidy IE; Alhabshan F; Abu-Sulaiman R
    Ann Saudi Med; 2021; 41(1):31-35. PubMed ID: 33550912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Palivizumab prophylaxis for respiratory syncytial virus in Canada: utilization and outcomes.
    Oh PI; Lanctôt KL; Yoon A; Lee DS; Paes BA; Simmons BS; Parison D; Manzi P;
    Pediatr Infect Dis J; 2002 Jun; 21(6):512-8. PubMed ID: 12182374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CDC changes recommendations due to severe nirsevimab shortage during the 2023-2024 RSV season.
    Rahmat ZS; Ahmad S; Malikzai A
    Pediatr Pulmonol; 2024 Apr; 59(4):1108-1109. PubMed ID: 38240360
    [No Abstract]   [Full Text] [Related]  

  • 13. Respiratory syncytial virus seasonality in southeast Florida: results from three area hospitals caring for children.
    Light M
    Pediatr Infect Dis J; 2007 Nov; 26(11 Suppl):S55-9. PubMed ID: 18090202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis.
    Frogel MP; Stewart DL; Hoopes M; Fernandes AW; Mahadevia PJ
    J Manag Care Pharm; 2010; 16(1):46-58. PubMed ID: 20131495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
    Pediatrics; 1998 Sep; 102(3 Pt 1):531-7. PubMed ID: 9738173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Substantial variability in community respiratory syncytial virus season timing.
    Mullins JA; Lamonte AC; Bresee JS; Anderson LJ
    Pediatr Infect Dis J; 2003 Oct; 22(10):857-62. PubMed ID: 14551484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of palivizumab on admission to the ICU for respiratory syncytial virus bronchiolitis: a national survey.
    Prais D; Danino D; Schonfeld T; Amir J
    Chest; 2005 Oct; 128(4):2765-71. PubMed ID: 16236953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Seasonal respiratory syncytial virus prophylaxis based on predetermined dates versus regional surveillance data.
    Paes BA; Craig C; Pigott W; Latchman A
    Pediatr Infect Dis J; 2013 Sep; 32(9):e360-4. PubMed ID: 23546534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of Respiratory Syncytial Virus Disease Prevention Strategies: Maternal Vaccine Versus Seasonal or Year-Round Monoclonal Antibody Program in Norwegian Children.
    Li X; Bilcke J; Vázquez Fernández L; Bont L; Willem L; Wisløff T; Jit M; Beutels P;
    J Infect Dis; 2022 Aug; 226(Suppl 1):S95-S101. PubMed ID: 35292816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prophylaxis in RSV infection (Palivizumab)--is it worthwhile?
    Hashmi NA; Cosgrove JF; MacMahon P
    Ir Med J; 2000 Dec; 93(9):284. PubMed ID: 11209917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.